Cronos Group Inc. (CRON) SEC Filings

Garnick Murray R reported acquisition or exercise transactions in this Form 4 filing.

Cronos Group Inc. director Murray R. Garnick reported a grant of 48,859.93 Deferred Share Units on August 6, 2026. Each unit provides a cash payment equal to the fair market value of Cronos common shares at redemption. Following this award, he holds 179,594.40 Deferred Share Units, which are mandatorily redeemed in cash after he ceases to be a director.

RUDYK JAMES DANIEL reported acquisition or exercise transactions in this Form 4 filing.

Cronos Group Inc. director James Daniel Rudyk received a grant of 48,859.9300 Deferred Share Units (DSUs) on August 6, 2026. Following this award, he holds 362,742.2200 DSUs directly. Each DSU entitles him, upon redemption, to a lump-sum cash payment equal to the fair market value of a Cronos common share on the redemption date, and vested DSUs are mandatorily redeemed on the first trading day after he ceases to be a director.

ADLER JASON MARC reported acquisition or exercise transactions in this Form 4 filing.

Cronos Group Inc. director Jason Marc Adler received a grant of 48,859.9300 Deferred Share Units, each linked to an equal number of common shares for valuation purposes. After this grant, he holds 362,742.2200 Deferred Share Units, which will be redeemed for a lump-sum cash payment based on the fair market value of Cronos Group common shares after he ceases to be a director.

Cronos Group Inc. adopted an annual schedule for shareholder Say-on-Pay Votes on executive compensation. At the 2026 Annual Meeting of Shareholders held on June 18, 2026, investors indicated a preference for annual votes. The board has now decided to follow that preference until the next required Say-on-Frequency Vote.

Cronos Group Inc., a global cannabis company, reported markedly stronger Q2 2026 results. Net revenue was $53,007 versus $33,455 a year earlier, with gross profit of $28,451 and operating income of $7,404 versus a prior operating loss. Net income attributable to Cronos Group was $32,085 compared with a loss in Q2 2025, helped by higher cannabis flower and extract sales and a foreign currency gain of $20,219.

For the first six months of 2026, net revenue rose to $98,217 and operating income to $5,571, with Adjusted EBITDA improving to $18,167 from $3,977. Q2 Adjusted EBITDA reached $13,088, while restructuring costs fell to $308. Canada and Israel remained the largest markets.

Liquidity stayed very strong: cash and cash equivalents, short-term investments and non‑current interest-bearing deposits totaled $827,019 against total liabilities of $62,415 as of June 30, 2026. The company repurchased 12,253,870 shares for $32,858 year‑to‑date and authorized a new share repurchase program of up to $50,000, with open‑market buybacks capped at 18,712,918 shares. A proposed $10,000,000 settlement of a U.S. securities class action is pending final court approval, and new anti‑dumping investigations in Israel could affect future imports. Two major customers accounted for 44% of Q2 net revenue before excise taxes.

Cronos Group Inc. reported a record second quarter for the period ended June 30, 2026, with net revenue of $53.0 million, up 58% year-over-year, and gross profit of $28.5 million, up 96%. Gross margin expanded to 54%, reflecting a mix shift toward Israel and other export markets that are not subject to excise taxes, along with higher sales volumes.

The company generated net income of $35.7 million, compared to a net loss of $38.5 million a year earlier, and Adjusted EBITDA of $13.1 million, up from $1.7 million. Revenue growth was broad-based, including Canada, a tenth consecutive record quarter in Israel under the PEACE NATURALS® brand, and strong demand in Germany and other markets. Cronos ended the quarter with $827.0 million in cash, short-term investments and interest-bearing deposits and had repurchased 12.3 million shares in the first half of 2026, reducing shares outstanding to about 370.7 million. The company is prepared to close its pending acquisition of CanAdelaar B.V. in the Netherlands, while also facing a new Israeli anti-dumping investigation that could affect medical cannabis imports into that market.

Cronos Group Inc. filed an initial Form 3 to report the insider status of Darren Chester Broughton as a director of the company. This filing establishes him as a reporting person for future insider ownership and trading disclosures but does not list any transactions or derivative positions.

Cronos Group Inc. reported results from its 2026 Annual Meeting of Shareholders held on June 18, 2026. Shareholders elected seven directors, each receiving over 207 million votes in favor, with Jason Adler and Darren Broughton each receiving about 220.5 million votes for.

Shareholders approved, on an advisory basis, the compensation of the named executive officers with 219,776,593 votes for and 1,624,630 against. In a separate advisory vote on the frequency of future say-on-pay votes, the largest number of votes, 207,874,325, supported holding the vote every one year. Shareholders also approved the appointment of Davidson & Company LLP as independent auditor for fiscal 2026, with 268,504,336 votes for and 3,324,423 withheld.

Cronos Group Inc. reported routine equity compensation activity by officer Terrence Gregory Joseph Doucet. On May 12, 2026, he exercised 10,597 restricted stock units (RSUs), receiving the same number of common shares at a stated price of $0.00 per share. To cover tax obligations, 5,199 common shares were disposed of at $3.75 per share in a tax-withholding transaction, which the data notes is priced in Canadian dollars. After these transactions, Doucet directly holds 110,588 common shares of Cronos Group. Each RSU represents a contingent right to receive one common share, and the exercised units reflect part of a 31,793 RSU grant that vests in three substantially equal annual installments beginning on the first anniversary of the May 12, 2025 grant date.